Age-Related Macular Degeneration Market Research Report Information By Type (Wet Age-Related Macular Degeneration and Dry Age-Related Macular Degeneration), By State (Intermediate Stage Age-Related Macular Degeneration, Early-Stage Age-Related Macular Degeneration and Late Stage Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years and Above 40 Years), By Treatment (Treatment and Diagnosis), By Route of Administration (Intravitreal Route of Administration and Intravenous Route of Administration), and By Region (Nor

Global Age-Related Macular Degeneration Market Overview

The Age-Related Macular Degeneration Market Size was valued at USD 8.26 Billion in 2023. The Global Age-Related Macular Degeneration industry is projected to grow from USD 8.45 Billion in 2024 to USD 15.24 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.43% during the forecast period (2024 - 2032). It is projected that the primary market drivers for the expansion would be the introduction of new treatments for age-related macular degeneration (AMD), an increase in AMD prevalence, and a robust product pipeline.

In March 2024, Vabysmo (faricimab) was launched by Roche Pharma India for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). This new product is the first one in the ophthalmology space that the pharma major has entered. Worldwide, there are two leading causes of vision loss: nAMD and DME. The Company called it Vabysmo, claiming that it is a dual pathway inhibitor, which inhibits two disease pathways connected to various retinal conditions that endanger vision. One industry source told Financial Express.com that this treatment can cost up to Rs 4 lakhs during the first year, and in the next year, it can be reduced to about Rs 2 lakhs. Nevertheless, as reported by an anonymous insider, this sum may vary due to illness progression and other treatment options opted by the patient.

Biocon said that its unit had received marketing authorization for a biosimilar product from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) in November 2023. The Bengaluru-based Company said in a regulatory filing that “Yesafili is a biosimilar of Aflibercept.” Therefore, Biocon Biologics has gotten marketing authorization for Yesafili.

In August 2023, Astellas announced that the U.S Food and Drug Administration (FDA) had approved IZERVAY™ (avacincaptad pegol intravitreal solution), effective August 4th, as a treatment for geographic atrophy (G.A.) secondary to AMD. For the Primary Endpoint at Month 12, only IZERVAY showed a statistically significant reduction (p<0.01) in the rate of G.A. progression among all approved G.A. treatments across two Phase III pivotal studies with a Novel Complement C5 Inhibitor.

Ranibizumab, a biosimilar for Lucentis, the innovator product with brand name Accentrix in India, has been launched by Pune-based Enzene Biosciences after introducing Bevacizumab for the treatment of metastatic colorectal cancer in November 2023. Ranibizumab biosimilar is a recombinant Fab used as therapy for neovascular AMD and could significantly decrease treatment expenditure for thousands of Indian patients. Enzene’s Ranibizumab biosimilar was shown to have equivalent clinical efficacy to Lucentis through well-established Phase 3 clinical studies and manufactured utilizing their state-of-the-art MAR system located at its Chakan plant, Pune.

Age-Related Macular Degeneration Market Trends

• Creation of nuclear weapons to propel the market growth

Vision loss is a severe issue for the elderly because it becomes worse with time. Wet macular degeneration and dry macular degeneration are the two main types of macula deterioration. Both could be fatal and necessitate medical treatment. As a result of an increase in elderly patients, the market is growing. In 2021, the WHO estimated that age-related macular degeneration would impact more than 200 million people worldwide, causing more than 10.4 million cases of moderate-to-severe visual impairment. In addition, the Department of Economic and Social Affairs of the United Nations predicted that 750 million people would be 65 years of age or older in 2021. Only a few number of drugs, particularly anti-VEGFs, are now approved to treat this illness. The frequent and unpleasant intraocular injections required for these drugs increase the burden and lead to non-adherence to treatment. Some of the big players are working on longer-acting anti-VEGFs and vitreous implants that enable sustained medication administration. Additionally, the introduction of long-acting anti-VEGF medications like Vabysmo and Beovu is anticipated to fuel market expansion in the ensuing years. Thus, this factor is driving the market CAGR.

Furthermore, macular degeneration is the most typical reason for loss of eyesight that is permanent. NGOs, optometrist groups, and health agencies all carry out a number of initiatives, including programmes, activities, and campaigns, to educate the public about the impacts of AMD and the appropriate courses of treatment. One such instance is a significant movement known as National AMD Awareness Month, which is observed in February and aims to raise awareness of AMD as the primary cause of vision loss. The major goal of AMD month is to promote awareness of the condition's symptoms, risk factors, and available therapies. The demand for macular degeneration medications is also being driven by rising funding for the condition's research and associated initiatives, which also urge patients to get eye exams to increase the likelihood of early identification.

However, pharmaceutical companies are creating a variety of medications to treat AMD since there is no known cure. As a result, a number of medications are being developed and tested for the treatment of AMD. Wet AMD can be successfully treated with anti-VEGF medications since they stop the fluid leak and restore vision. Thus, it is anticipated that this aspect will accelerate age-related macular degeneration market revenue globally.

Age-Related Macular Degeneration Market Segment Insights

Age-Related Macular Degeneration Type Insights

The age-related macular degeneration market segmentation has been segmented by type into Wet Age-Related Macular Degeneration and Dry Age-Related Macular Degeneration. The wet age-related macular degeneration segment dominated the market growth in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The increasing use of VEGF inhibitors, which are generally used to treat wet AMD, is the main factor fueling the expansion of this market segment. All of these VEGF inhibitors, have been given the US FDA's blessing for the treatment of wet AMD.

Age-Related Macular Degeneration Stage Insights

The age-related macular degeneration market segmentation, based on stage, Intermediate Stage Age-Related Macular Degeneration, Early-Stage Age-Related Macular Degeneration and Late Stage Age-Related Macular Degeneration. The intermediate stage age-related macular degeneration segment dominated the age-related macular degeneration market revenue in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. There may be some or no vision loss with moderate AMD. In this stage, the retinal pigment epithelium (RPE), which is made up of cells that promote the health of the retina, has undergone changes and there are either numerous medium-sized drusen or at least one giant drusen in one or both eyes.

Figure 2: Age-Related Macular Degeneration Market by Stage, 2021 & 2030 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Age-Related Macular Degeneration Age Group Insights

The age-related macular degeneration market data, based on age group, Above 75 years, Above 60 years and Above 40 years. The above 75 years segment dominated the age-related macular degeneration market revenue in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Individuals of age 75 and older are at a risk risk for AMD due to factors like smoking, having high blood pressure, and consumption of a diet high in saturated fat.

Age-Related Macular Degeneration Treatment Insights

Based on treatment, the age-related macular degeneration industry, is segmented into treatment and diagnosis. The treatment segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032 due to increased demand.

Age-Related Macular Degeneration Route of Administration Insights

The age-related macular degeneration industry, based on route of administration, Intravitreal Route of Administration and Intravenous Route of Administration. The utility segment dominated the age-related macular degeneration market in 2021 and is projected to be the faster-growing segment during the forecast period, 2024-2032 owing to the fact that the tailored drug delivery makes it more efficient. Additionally, intravitreal or intraocular injections are used to provide the majority of anti-VEGF injections.

Age-Related Macular Degeneration Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America age-related macular degeneration market accounted for USD 3.5 billion in 2021 and is expected to exhibit a 43.10% CAGR during the study period. Age-related Macular Degeneration (AMD) market growth is influenced by a number of factors, including the increasing prevalence of geriatric population and age-related macular degeneration, participation of significant market players, and increased research and development activities.

Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: AGE-RELATED MACULAR DEGENERATION MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific age-related macular degeneration market accounts for the fastest growing market share. Due to accessibility issues and high prescription costs, the sale of treatments for exudative AMD in APAC is currently negligible. However, AMD is highly prevalent in the area, making it a market that could expand. Additionally, there aren't many businesses in APAC engaged in the marketing and development of treatments for exudative AMD. Moreover, China age-related macular degeneration market held the largest market share, and the India age-related macular degeneration market was the fastest-growing market in this region.

Europe age-related macular degeneration market is expected to grow at a substantial CAGR from 2024 to 2032. This may be a result of Europe's significant unmet requirements and increased purchasing ability to purchase patented medications. In addition, it is anticipated that changes in lifestyle and the arrival of new macular degeneration medications would increase the need for these medications in the area. Further, the UK age-related macular degeneration market held the largest market share, and the Germany age-related macular degeneration market was the fastest-growing market in the region.

Age-Related Macular Degeneration Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the age-related macular degeneration industry grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, market developments and collaboration with other organizations. Competitors in the industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market industry.

One of the primary business strategies manufacturers adopt in the age-related macular degeneration industry to benefit clients and expand the sector is manufacturing locally to reduce operating costs. In recent years, age-related macular degeneration industry has provided medicine with some of the most significant benefits. The age-related macular degeneration market major player such as Hoffmann-La Roche AG, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc, ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc., GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG and Rxi Pharmaceuticals Inc.

The healthcare multinational F. Hoffmann-La Roche AG, also known as Roche, has two business segments that operate globally: pharmaceuticals and diagnostics. Shares of its parent firm, Roche Holding AG, are traded on the SIX Swiss Exchange. In October 2021, for age-related macular degeneration (AMD) patients who have previously reacted to at least two anti-vascular endothelial growth factors (VEGF) injections, Roche got approval from the US Food and Drug Administration for Susvimo, 100 mg/mL.

Injections are provided by Regeneron Pharmaceuticals Inc. for the treatment of patients with neovascular age-related macular degeneration. The business offers drugs and pipelines that are intended to help people with eye disorders, inflammatory and allergy diseases, cancer, metabolic and cardiovascular diseases, infectious diseases, pain, and uncommon diseases.

Key companies in the age-related macular degeneration market includes

• 
  

  Hoffmann-La Roche AG

  
  


• 
  

  Bausch & Lomb Incorporate

  
  


• 
  

  Novartis AG

  
  


• 
  

  Pfizer Inc

  
  


• 
  

  ALLERGAN

  
  


• 
  

  Acucela Inc.

  
  


• 
  

  Santen Pharmaceuticals Co.

  
  


• 
  

  Ophthotech Corporation

  
  


• 
  

  Alimera Sciences Inc.

  
  


• 
  

  GlaxoSmithKline PLC

  
  


• 
  

  Regeneron Pharmaceutical Inc.

  
  


• 
  

  Bayer AG

  
  


• 
  

  Rxi Pharmaceuticals Inc.

  
  

Age-related Macular Degeneration Industry Developments

February 2022:The effectiveness, long-term stability, and safety of KSI-301, a novel antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration were investigated in a Phase 2b/3 clinical trial, which was conducted by Kodiak Sciences Inc.

January 2022:The Food and Drug Administration (FDA) has authorised Roche's Faricimab (Vabysmo) for the treatment of people with neovascular age-related macular degeneration and diabetic macular edoema (DME) (nAMD)

Age-Related Macular Degeneration Market Segmentation

Age-Related Macular Degeneration Type Outlook (USD Billion, 2018-2032)

• Wet Age-Related Macular Degeneration


• Dry Age-Related Macular Degeneration

Age-Related Macular Degeneration Stage Outlook (USD Billion, 2018-2032)

• Intermediate Stage Age-Related Macular Degeneration


• Early Stage Age-Related Macular Degeneration


• Late Stage Age-Related Macular Degeneration

Age-Related Macular Degeneration Age Group Outlook (USD Billion, 2018-2032)

• ABOVE 75 YEARS


• ABOVE 60 YEARS


• ABOVE 40 YEARS

Age-Related Macular Degeneration Treatment Outlook (USD Billion, 2018-2032)

• Treatment


• Diagnosis

Age-Related Macular Degeneration Route of Administration Outlook (USD Billion, 2018-2032)

• Intravitreal Route of Administration


• Intravenous Route of Administration

Age-Related Macular Degeneration Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  
  

• 
  
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America